Yes.
Peers post Ph 2b success:
- PAR - Ph 2b success awaiting Ph 3 trial approval $711.5m MC;
- OPT - Ph 2b success awaiting Ph 3 trial approval $809.9m MC.
Undervalued bios have typically run in the lead up to the phase 2 results. E.g. Paradigm released their Phase 2b data on the 18th of December 2018, the closing share price before the announcement was $1.29. 3-month prior $0.946-month $0.67; and12 month $0.24. BTW 0.24 was $47.7m MC - just to highlight how undervalued we are here. It ran to $200m prior to release.
As for OPT, that was $200m prior to results also - end markets of OPT and PAR are not dissimilar.
Stating the obvious here but,Dimerix currently sits 6 months before not one, but two phase two readouts right now. Should see a rerate over next few months given we are at 19.5m EV (could be up to 10x higher based on peer analysis) and a massive rerate upon success. Crazy risking when you think diabetic subset of ph2a achieved 35% and this trial just needs 30% improvement.
8's.
- Forums
- ASX - By Stock
- DXB
- Taylor's Initiation
Taylor's Initiation, page-23
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M |
Open | High | Low | Value | Volume |
41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 83901 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 0.395 |
7 | 153879 | 0.390 |
8 | 193916 | 0.385 |
9 | 349785 | 0.380 |
5 | 212000 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 33901 | 3 |
0.405 | 22128 | 1 |
0.410 | 125260 | 4 |
0.415 | 154602 | 6 |
0.420 | 119006 | 3 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |